Phase 2 N=49 Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System
Irritation/Irritant
Primary: Skin Irritation (Erythema and Edema) — 0.9; 0.7; 1.1; 1.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
Liver and Intrahepatic Biliary Tract Cancer · Recurrent Extrahepatic Bile Duct Cancer · Unresectable Extrahepatic Bile Duct Cancer
Primary: Objective Response Rate (CR and PR) — 0; 3 patients
Phase 2 N=63 Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
HIV Infections · Cachexia · Anorexia
Primary: Change in Body Weight — 5.4; 3.5; 7.0; 3.5 kg
Phase 2 N=22 Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
Age Related Macular Degeneration · Choroidal Neovascularization · Macular Edema
Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants
Phase 2 N=21 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Pheochromocytoma · Paraganglioma
Primary: MTD of Ultratrace Iobenguane I 131 — 8 mCi/kg
Phase 2 N=40 Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants
Phase 2 N=36 Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Diffuse Astrocytoma
Primary: Maximum Tolerated Dose of Temsirolimus — 115 mg/week
Phase 2 N=133 Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Endometrial Cancer
Primary: Objective Response Rate (ORR) — 14.3 Percentage of participants
Phase 2 N=26 Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
Thrombocytopaenia
Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I — 3; 8; 4; 9 Participants
Phase 2 N=65 An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence
Alcohol Dependence
Primary: Drinks Per Drinking Day — 7.2; 7.8; 5.2 drinks per drinking day — p=0.49
Phase 2 N=13 Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
Prostate Cancer
Primary: Toxicity — 2; 204 events
Phase 2 N=8 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma · Recurrent Adult Liver Carcinoma
Primary: Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 — 0 patients
Phase 2 N=67 Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0) — 7; 2; 40; 42 percentage of participants
Phase 2 N=69 Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
Non-Small-Cell Lung Cancer
Primary: Median Time to Progression (TTP) — 6.11 months
Phase 2 N=339 Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 86.7; 88.9; 86.4; 87.0 percentage of participants